ReviewSovremennye tekhnologii v meditsine2026
Cerebral Neurodegeneration and Cognitive Impairment in Patients on Maintenance Hemodialysis: the Role of Neuroglia and Associated Factors (Review).
Review in Sovremennye tekhnologii v meditsine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD), which often requires maintenance hemodialysis (MHD), represents a model of accelerated aging. Therefore, understanding the mechanisms underlying cerebral neurodegeneration (CND) and cognitive impairment (CI) in patients undergoing MHD is of particular importance. Brain damage in patients with end-stage CKD is considered a multicomponent process associated with the impact of cerebrovascular, neurodegenerative, and numerous dysmetabolic factors. Special attention is given to CND mechanisms mediated by the activation of microglia and astrocytes. The high prevalence of CI in the general population and especially among patients with end-stage CKD undergoing MHD determines the need to clarify CND risk factors and biomarkers. Furthermore, it is essential to explore therapeutic targets, as well as modifiable modern strategies and technologies aimed at slowing the CND progression. This review synthesizes data on the role of neuroglia and associated factors in the development of CND and CI in MHD patients. It presents the mechanisms and factors affecting neuroglia and involved in the pathogenesis of CND and CI. Particular focus is placed on chronic systemic inflammation, the effects of uremic toxins, and the activation of the cerebral renin-angiotensin-aldosterone system. The article studies such chronic systemic inflammatory factors associated with neuroglia as protein S100B, IL-1β, IL-6, TNF-α, and fibrinogen. Experimental and clinical data investigating the impact of uremic toxins (indoxyl sulfate, p-cresol sulfate, and imidazole propionate) on microglia and astrocytes, as well as the activation of the cerebral renin-angiotensin-aldosterone system, are analyzed. Potential further clinical research fields aimed at slowing the CND and CI progression in this patient population are highlighted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.